99% Pure Sitagliptin Api Active Pharmaceutical Ingredient Cas 486460-32-6 In Stock

99% Pure Sitagliptin CAS 486460-32-6 in Stock

Product Description

Sitagliptin, trade name Genover, is an oral hypoglycemic agent (antidiabetic medication), which belongs to the dipeptidyl peptidase-4 (DPP-4) inhibitor, produced by Merck R&D and sales. Sitagliptin can be used alone or combined with other oral hypoglycemic medications to form a compound medication (such as metformin or thiazolidinedione) to treat type 2 diabetes. The advantage of sitagliptin is that it has fewer side effects (such as a lower chance of causing hypoglycemia and weight gain) when controlling the blood glucose level. Although safety is its advantage, the effect cannot be well guaranteed, so it is generally recommended to use it in combination with other medications such as metformin.

Function and Application

Sitagliptin is a new type of anti-type II diabetes medication approved by the FDA and the first dipeptidyl peptidase-IV inhibitor medication for the treatment of type II diabetes. Sitagliptin's mechanism of action is different from previous oral hypoglycemic medications. It improves the ability of diabetic patients' own pancreatic β cells to produce Chemicalbook in-sulin, and increases the secretion of in-sulin when blood sugar rises, thereby controlling the blood sugar level of diabetic patients. Clinical studies have shown that sitagliptin is an oral effective medication with good market prospects. It has a significant hypoglycemic effect when used alone or in combination with metformin and pioglitazone, and it is safe to take, well tolerated, and has fewer adverse reactions.